Samah A Loutfy1,2, Mostafa H Elberry1, Khaled Yehia Farroh3, Hossam Taha Mohamed4,5, Aya A Mohamed4, ElChaimaa B Mohamed1, Ahmed Hassan Ibrahim Faraag6, Shaker A Mousa7. 1. Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. 2. Nanotechnology Research Center, British University, Cairo, Egypt. 3. Nanotechnology and Advanced Materials Central Lab, Agricultural Research Center, Giza, Egypt. 4. Faculty of Biotechnology, October University for Modern Sciences and Arts, 6th October, Giza, Egypt. 5. Department of Zoology, Faculty of Science,Cairo University, Giza, Egypt. 6. Botany and Microbiology Department, Bioinformatics Center, Faculty of Science, Helwan University, Cairo, Egypt. 7. The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
Abstract
PURPOSE: Current direct-acting antiviral agents for treatment of hepatitis C virus genotype 4a (HCV-4a) have been reported to cause adverse effects, and therefore less toxic antivirals are needed. This study investigated the role of curcumin chitosan (CuCs) nanocomposite as a potential anti-HCV-4a agent in human hepatoma cells Huh7. METHODS: Docking of curcumin and CuCs nanocomposite and binding energy calculations were carried out. Chitosan nanoparticles (CsNPs) and CuCs nanocomposite were prepared with an ionic gelation method and characterized with TEM, zeta size and potential, and HPLC to calculate encapsulation efficiency. Cytotoxicity studies were performed on Huh7 cells using MTT assay and confirmed with cellular and molecular assays. Anti-HCV-4a activity was determined using real-time PCR and Western blot. RESULTS: The strength of binding interactions between protein ligand complexes gave scores with NS3 protease, NS5A polymerase, and NS5B polymerase of -124.91, -159.02, and -129.16, for curcumin respectively, and -68.51, -54.52, and -157.63 for CuCs nanocomposite, respectively. CuCs nanocomposite was prepared at sizes 29-39.5 nm and charges of 33 mV. HPLC detected 4% of curcumin encapsulated into CsNPs. IC50 was 8 µg/mL for curcumin and 25 µg/mL for the nanocomposite on Huh7 but was 25.8 µg/mL and 34 µg/mL on WISH cells. CsNPs had no cytotoxic effect on tested cell lines. Apoptotic genes' expression revealed the caspase-dependent pathway mechanism. CsNPs and CuCs nanocomposite demonstrated 100% inhibition of viral entry and replication, which was confirmed with HCV core protein expression. CONCLUSION: CuCs nanocomposite inhibited HCV-4a entry and replication compared to curcumin alone, suggesting its potential role as an effective therapeutic agent.
PURPOSE: Current direct-acting antiviral agents for treatment of hepatitis C virus genotype 4a (HCV-4a) have been reported to cause adverse effects, and therefore less toxic antivirals are needed. This study investigated the role of curcumin chitosan (CuCs) nanocomposite as a potential anti-HCV-4a agent in human hepatoma cells Huh7. METHODS: Docking of curcumin and CuCs nanocomposite and binding energy calculations were carried out. Chitosan nanoparticles (CsNPs) and CuCs nanocomposite were prepared with an ionic gelation method and characterized with TEM, zeta size and potential, and HPLC to calculate encapsulation efficiency. Cytotoxicity studies were performed on Huh7 cells using MTT assay and confirmed with cellular and molecular assays. Anti-HCV-4a activity was determined using real-time PCR and Western blot. RESULTS: The strength of binding interactions between protein ligand complexes gave scores with NS3 protease, NS5A polymerase, and NS5B polymerase of -124.91, -159.02, and -129.16, for curcumin respectively, and -68.51, -54.52, and -157.63 for CuCs nanocomposite, respectively. CuCs nanocomposite was prepared at sizes 29-39.5 nm and charges of 33 mV. HPLC detected 4% of curcumin encapsulated into CsNPs. IC50 was 8 µg/mL for curcumin and 25 µg/mL for the nanocomposite on Huh7 but was 25.8 µg/mL and 34 µg/mL on WISH cells. CsNPs had no cytotoxic effect on tested cell lines. Apoptotic genes' expression revealed the caspase-dependent pathway mechanism. CsNPs and CuCs nanocomposite demonstrated 100% inhibition of viral entry and replication, which was confirmed with HCV core protein expression. CONCLUSION: CuCs nanocomposite inhibited HCV-4a entry and replication compared to curcumin alone, suggesting its potential role as an effective therapeutic agent.
Authors: Adam Gesing; Michal M Masternak; Feiya Wang; Andrzej Lewinski; Malgorzata Karbownik-Lewinska; Andrzej Bartke Journal: Exp Biol Med (Maywood) Date: 2011-02
Authors: Zheng-Jiang Zhu; Partha S Ghosh; Oscar R Miranda; Richard W Vachet; Vincent M Rotello Journal: J Am Chem Soc Date: 2008-10-01 Impact factor: 15.419
Authors: Zunaira Alvi; Muhammad Akhtar; Arshad Mahmood; Nisar Ur-Rahman; Imran Nazir; Hadia Sadaquat; Muhammad Ijaz; Shahzada Khurram Syed; Muhammad Khurram Waqas; Yi Wang Journal: Int J Nanomedicine Date: 2021-12-29
Authors: Estefânia V R Campos; Anderson E S Pereira; Jhones Luiz de Oliveira; Lucas Bragança Carvalho; Mariana Guilger-Casagrande; Renata de Lima; Leonardo Fernandes Fraceto Journal: J Nanobiotechnology Date: 2020-09-05 Impact factor: 10.435